Niacinamide

Umxholo

• Kusenokwenzeka ukuba iyasebenza ...
• Inokwenzeka ukuba isebenze ...
• Kusenokwenzeka ukuba ayisebenzi ...
• Akukho bungqina baneleyo bokulinganisa ukusebenza ...
• Amanyathelo okhuseleko kunye nezilumkiso:

Zimbini iintlobo zevithamini B3. Enye ifom i-niacin, enye i-niacinamide. I-Niacinamide ifumaneka kukutya okuninzi kubandakanya igwele, inyama, intlanzi, ubisi, amaqanda, imifuno eluhlaza, iimbotyi, kunye neenkozo zesiriyeli. I-Niacinamide ikwafumaneka kwiivithamini B ezininzi ezongezelelekileyo kunye nezinye iivithamini B. I-Niacinamide inokwenziwa emzimbeni kwi-niacin yokutya.

Musa ukudida i-niacinamide ne-niacin, i-NADH, i-nicotinamide riboside, i-inositol nicotinate, okanye i-tryptophan. Jonga uluhlu olwahlukileyo lwezi zihloko.

I-Niacinamide ithathwa ngomlomo ukuthintela ukunqongophala kwe-vitamin B3 kunye neemeko ezinxulumene noko ezifana nepellagra. Kwakhona kuthathwa ngomlomo ngenxa yamabala, isifo seswekile, umhlaza womlomo, isifo samathambo, kunye nezinye iimeko ezininzi. Nangona kunjalo, abukho ubungqina benzululwazi obuxhasa ezi zinto zisetyenziswayo.

I-Niacinamide ikwasetyenziswa kulusu lwamabala, i-eczema, kunye nezinye iimeko zolusu. Akukho bungqina bokuba uxhase ezi zinto zisetyenziswayo.

Amayeza endalo aVimba weDatha Ukusebenza kwexabiso ngokusekwe kubungqina besayensi ngokwala manqanaba alandelayo: Ukusebenza, ukusebenza ngokukuko, okunokwenzeka ukuba kusebenze, okungenzeka kungasebenzi, kunokwenzeka ukungasebenzi, ukungasebenzi, kunye nobungqina obungonelanga bokulinganisa.

Ukulinganiswa kokusebenza kwe NIACINAMIDE zezi zilandelayo:

Kusenokwenzeka ukuba iyasebenza ...

• Isifo esibangelwa kukusilela kwe-niacin (pellagra). I-Niacinamide yamkelwe yi-US Food and Drug Administration (FDA) kwezi zinto zisetyenziswayo. I-Niacinamide ngamanye amaxesha ikhethwa ngaphezu kwe-niacin kuba ayibangeli "ukugungxula," (ukuba bomvu, ukurhawuzelela kunye nokurhawuzelela), isiphumo esibi seyeza lokunyanga

Inokwenzeka ukuba isebenze ...

• Amabala. Uphando lwakwangoko lubonisa ukuba ukuthatha iipilisi ezine-niacinamide kunye nezinye izithako kwiiveki ezisibhozo kuphucula ukubonakala kolusu kubantu abane-acne. Olunye uphando lubonisa ukuba ukusebenzisa ikhrimu equlathe i-niacinamide kuphucula ukubonakala kolusu kubantu abane-acne.
• Seswekile. Olunye uphando lubonisa ukuba ukuthatha i-niacinamide kunokunceda ukuthintela ukulahleka kwemveliso ye-insulin ebantwaneni nakubantu abadala abasemngciphekweni wohlobo lweswekile 1. Inokuthintela nokulahleka kwemveliso ye-insulin kunye nokunciphisa idosi ye-insulin efunwa ngabantwana abasandula ukufumanisa ukuba banesifo seswekile sokuqala. Nangona kunjalo, i-niacinamide ibonakala ngathi ayithinteli ukukhula kohlobo lweswekile 1 kubantwana abasemngciphekweni. Kubantu abanesifo seswekile sesi-2, i-niacinamide ibonakala ikunceda ukukhusela imveliso ye-insulin kunye nokuphucula ulawulo lweswekile egazini.
• Amanqanaba aphezulu e-phosphate egazini (hyperphosphatemia). Amanqanaba aphezulu egazi e-phosphate anokubangelwa kukuncipha komsebenzi wezintso. Kubantu abanokungaphumeleli kwezintso abakwi-hemodialysis kwaye banamanqanaba aphezulu e-phosphate yegazi, ukuthatha i-niacinamide kubonakala kunceda ukunciphisa amanqanaba e-phosphate xa kuthathwa kunye okanye ngaphandle kwe-phosphate binders.
• Intloko kunye nomhlaza wentamo. Uphando lubonisa ukuba ukuthatha i-niacinamide ngelixa ufumana i-radiotherapy kunye nohlobo lonyango olubizwa ngokuba yi-carbogen kunokunceda ukulawula ukukhula kwe-tumor kunye nokwandisa ukusinda kwabanye abantu abanomhlaza we-larynx. Ukuthatha i-niacinamide ngelixa ufumana i-radiotherapy kunye ne-carbogen kubonakala ngathi kuyanceda abantu abanomhlaza wengqula abano-anemia. Ikwabonakala ngathi iyabanceda abantu abanezilonda ezivalelwe i-oxygen.
• Umhlaza wolusu. Ukuthatha i-niacinamide kubonakala kunceda ekuthinteleni umhlaza wolusu omtsha okanye amabala aqalayo (i-actinic keratosis) ekuyileni abantu abanembali yomhlaza wolusu okanye i-actinic keratosis.
• Osteoarthritis. Ukuthatha i-niacinamide kubonakala kuphucula ukuhlangana ngokudibeneyo kunye nokunciphisa iintlungu kunye nokudumba kwabantu abane-osteoarthritis. Kwakhona, abanye abantu abane-osteoarthritis abathatha i-niacinamide banokufuna ukuthatha amayeza ambalwa eentlungu.

Kusenokwenzeka ukuba ayisebenzi ...

• Ithumba lobuchopho. Uphando lwakwangoko lubonisa ukuba ukunyanga abantu abanezicubu zengqondo ezisuswe ngotyando nge-niacinamide, i-radiotherapy, kunye ne-carbogen akuphuculi ukusinda xa kuthelekiswa ne-radiotherapy okanye i-radiotherapy kunye ne-carbogen.
• Umhlaza wesinyi. Ukunyanga abantu abanomhlaza wesinyi nge-niacinamide, i-radiotherapy, kunye ne-carbogen akubonakali kunciphisa ukukhula kwe-tumor okanye ukuphucula ukusinda xa kuthelekiswa ne-radiotherapy okanye i-radiotherapy kunye ne-carbogen.

Akukho bungqina baneleyo bokulinganisa ukusebenza ...

• Isifo samehlo esikhokelela kwilahleko yombono kubantu abadala (imeko enxulumene nobudala be-macular degeneration okanye i-AMD). Uphando lwakwangoko lubonisa ukuba ukuthatha i-niacinamide, i-vitamin E, kunye ne-lutein yonyaka kuphucula indlela esebenza ngayo i-retina kubantu abanembonakalo yokunxibelelana nobudala ngenxa yomonakalo we-retina.
• Ulusu olugugileyo. Uphando lwakwangoko lubonisa ukuba ukufaka ukhilimu oqukethe i-5% niacinamide ebusweni kuphucula ubundlobongela, imibimbi, ukuqina, kunye nokuba bomvu kwabasetyhini abanesikhumba esiguga ngenxa yokonakaliswa lilanga.
• I-eczema (i-atopic dermatitis). Uphando lwakwangoko lubonisa ukuba ukufaka ukhilimu oqukethe i-2% niacinamide kunciphisa ilahleko yamanzi kunye nokuphucula ukuhambisa amanzi, kwaye kunciphisa ubomvu kunye nokukala, kubantu abane-eczema.
• Ukuqwalaselwa kwentsilelo-yokuchaphazeleka kwengqondo (ADHD). Kukho ubungqina obuphikisanayo malunga nokusebenziseka kwe-niacinamide ngokudibeneyo nezinye iivithamini kunyango lwe-ADHD.
• Ubomvu besikhumba obangelwa kukulimala okanye ukucaphuka (i-erythema). Uphando lwakwangoko lubonisa ukuba ukusebenzisa ikhrimu equkethe i-niacinamide kunciphisa ububomvu bolusu, ukoma, kunye nokurhawuzelela okubangelwa lunyango lwamayeza amabala isotretinoin.
• Isifo sezintso zexesha elide (isifo sezintso esinganyangekiyo okanye i-CKD). Uphando lwakwangoko lubonisa ukuba ukuthatha i-niacinamide akuncedi ukunciphisa ukurhawuzelela kubantu abanesifo sezintso.
• Amabala amnyama esikhumba ebusweni (i-melasma). Uphando lwakwangoko lubonisa ukuba ukuthambisa into ene-5% niacinamide okanye i-2% niacinamide ene-2% tranexamic acid kangangeeveki ezi-4 ukuya kwezi-8 kunceda ukukhanyisa ulusu kubantu abaneebala elimnyama lolusu.
• Umhlaza oqala kwiiseli ezimhlophe zegazi (engeyo-Hodgkin lymphoma). Uphando lwakwangoko lubonisa ukuba ukuthatha i-niacinamide njengenxalenye yonyango kunye neziyobisi ekuthiwa yi-vorinostat kunokunceda abantu abane-lymphoma bangene kuxolelo.
• Imeko yesikhumba ebangela ubomvu ebusweni (rosacea). Uphando lwakwangoko lubonisa ukuba ukuthatha iipilisi ezine-niacinamide kunye nezinye izithako kwiiveki ezisibhozo kuphucula ukubonakala kolusu kubantu abane-rosacea.
• Rough, isikhumba esinamaxolo esikhumbeni nasebusweni (seborrheic dermatitis). Uphando lwakwangoko lubonisa ukuba ukusebenzisa ukhilimu oqukethe i-4% niacinamide kunokunciphisa ukubomvu kunye nokukala kolusu kubantu abane-seborrheic dermatitis.
• Utywala.
• Isifo se-Alzheimer.
• Isifo samathambo.
• Yehla kwimemori nakwizakhono zokucinga ezenzeka ngesiqhelo ngobudala.
• Uxinzelelo.
• Igazi elonyukayo.
• Ukugula kwesithuthi.
• Isifo se-Premenstrual syndrome (PMS).
• Ezinye iimeko.

Ubungqina obungakumbi buyafuneka ukukala i-niacinamide kwezi zinto zisetyenziswayo.

I-Niacinamide inokwenziwa kwi-niacin emzimbeni. I-Niacin iguqulwa ibe yi-niacinamide xa ithathwa ngezixa ezikhulu kunoko kufunwa ngumzimba. I-Niacinamide inyibilika ngokulula emanzini kwaye ifunxwa kakuhle xa ithathwa ngomlomo.

I-Niacinamide iyafuneka ekusebenzeni kakuhle kwamafutha kunye neeswekile emzimbeni kunye nokugcina iiseli ezisempilweni.

Ngokungafaniyo ne-niacin, i-niacinamide ayinaziphumo ziluncedo kumafutha kwaye akufuneki isetyenziselwe ukunyanga i-cholesterol ephezulu okanye amanqanaba aphezulu egazi. Xa kuthathwa ngomlomo: Niacinamide yi NGOKUKHUSELEKILEYO kubantu abadala abaninzi xa bethathwe kwiimali ezicetyiswayo. Ngokungafaniyo ne-niacin, i-niacinamide ayibangeli ukugungxulwa. Nangona kunjalo, i-niacinamide inokubangela iziphumo ebezingalindelekanga ezinje ngesisu, irhasi, isiyezi, irhashalala, ukurhawuzelela, kunye nezinye iingxaki. Ukunciphisa umngcipheko wale miphumela, abantu abadala kufuneka bakuphephe ukuthatha i-niacinamide kwiidosi ezinkulu kune-35 mg ngosuku.

Xa kuthathwa idosi engaphezulu kwe-3 yegramu ngosuku lwe-niacinamide, iziphumo ebezingalindelekanga ezibi kakhulu zinokwenzeka. Oku kubandakanya iingxaki zesibindi okanye iswekile ephezulu yegazi.

Xa isetyenziswa eluswini: Niacinamide yi UKHUSELEKO OLUNOKWENZEKA. I-cream ye-Niacinamide inokubangela ukutshisa kancinci, ukurhawuzelela, okanye ubomvu.

Amanyathelo okhuseleko kunye nezilumkiso:

Ukukhulelwa kunye nokuncancisa: Niacinamide yi NGOKUKHUSELEKILEYO kubafazi abakhulelweyo nabancancisayo xa bethathwa ngezixa ezicetyiswayo. Elona nani liphezulu licetyiswayo le-niacin labafazi abakhulelweyo okanye abancancisayo ngama-30 mg ngemini kubafazi abangaphantsi kweminyaka eli-18 ubudala, kunye nama-35 mg ngosuku kwabasetyhini abangaphezulu kweminyaka eli-18 ubudala.

Abantwana: Niacinamide yi NGOKUKHUSELEKILEYO xa ithathwa ngomlomo kwixabiso elicetyiswayo kwiqela ngalinye leminyaka. Kodwa abantwana kufuneka bakuphephe ukuthatha idosi ye-niacinamide ngaphezulu kwemida ephezulu yemihla ngemihla, eyi-10 mg yabantwana abaneminyaka eyi-1-3 ubudala, i-15 mg yabantwana abaneminyaka engama-4-8 ubudala, i-20 mg yabantwana abaneminyaka eli-9-13 ubudala, kunye 30 mg kubantwana abaneminyaka eli-14-18 ubudala.

Umzimba: I-Niacinamide inokwenza ukuba i-aleji ibe qatha ngenxa yokuba ibangela i-histamine, ikhemikhali ejongene neempawu zokungabikho komzimba, ukuba ikhutshwe.

Seswekile: I-Niacinamide inokunyusa iswekile yegazi. Abantu abanesifo seswekile abathatha i-niacinamide kufuneka bahlole iswekile yegazi labo ngononophelo.

Isifo senyongo: I-Niacinamide inokusenza mandundu ngakumbi isifo se-gallbladder.

Igawuthi: Isixa esikhulu se-niacinamide sinokuzisa igawuthi.

Uxilongo lwezintsoUkuthatha i-niacinamide kubonakala kukonyusa umngcipheko weeplatelet zegazi ezisezantsi kubantu abanesifo sezintso abakwi-dialysis.

Isifo sesibindi: I-Niacinamide inokunyusa ukonakala kwesibindi. Ungayisebenzisi ukuba unesifo sesibindi.

Izilonda esiswini okanye emathunjini: I-Niacinamide inokwenza izilonda zibe mandundu. Ungayisebenzisi ukuba unezilonda.

Ugqirha: I-Niacinamide inokuphazamisana nolawulo lweswekile yegazi ngexesha nasemva kotyando. Yeka ukuthatha i-niacinamide ubuncinci iiveki ezi-2 ngaphambi kotyando olucwangcisiweyo.

Iphakathi

Lumka ngale nhlanganisela.

ICarbamazepine (iTegretol)

ICarbamazepine (Tegretol) yophukile ngumzimba. Kukho inkxalabo yokuba i-niacinamide inokunciphisa ngokukhawuleza ukuba umzimba uphula njani i-carbamazepine (Tegretol). Kodwa akukho lwazi lwaneleyo lokwazi ukuba oku kubalulekile.

Amayeza anokwenzakalisa isibindi (iziyobisi zeHepatotoxic)

I-Niacinamide inokwenzakalisa isibindi, ngakumbi xa isetyenziswa kwiidosi eziphezulu. Ukuthatha i-niacinamide kunye neyeza elinokwenzakalisa isibindi kunokunyusa umngcipheko wokonakala kwesibindi. Musa ukuthatha i-niacinamide ukuba uthatha iyeza elinokwenzakalisa isibindi.

Amanye amayeza anokwenzakalisa isibindi abandakanya i-acetaminophen (iTylenol kunye nezinye), amiodarone (Cordarone), carbamazepine (Tegretol), isoniazid (INH), methotrexate (Rheumatrex), methyldopa (Aldomet), fluconazole (Diflucan), itraconazole (Sporaconazole) erythromycin (Erythrocin, Ilosone, abanye), phenytoin (Dilantin), lovastatin (Mevacor), pravastatin (Pravachol), simvastatin (Zocor), kunye nabanye abaninzi.

Amayeza acothisa ukujiya kwegazi (iAnticoagulant / iziyobisi zeAntiplatelet)

I-Niacinamide inokucothisa ukujiya kwegazi. Ukuthatha i-niacinamide kunye namayeza acothisa ukucola kunokunyusa amathuba okugruzuka nokopha.

Amanye amayeza acothisa ukucoca igazi aquka iasprini, clopidogrel (Plavix), dalteparin (Fragmin), enoxaparin (Lovenox), heparin, indomethacin (Indocin), ticlopidine (Ticlid), warfarin (Coumadin), kunye nezinye.

I-Primidone (iMysoline)

I-Primidone (Mysoline) yophukile ngumzimba. Kukho inkxalabo yokuba i-niacinamide inokunciphisa ngokukhawuleza ukuba umzimba uphula njani i-primidone (Mysoline). Kodwa akukho lwazi lwaneleyo lokwazi ukuba oku kubalulekile.

Iherbs kunye nezongezo ezinokuthi zenzakalise isibindi

I-Niacinamide inokubangela ukonakala kwesibindi, ngakumbi xa isetyenziswa kwiidosi eziphezulu. Ukuthatha i-niacinamide kunye namanye amayeza okanye izongezo ezinokwenzakalisa isibindi kunokunyusa umngcipheko. Ezinye zeemveliso zibandakanya i-androstenedione, igqabi le-borage, i-chaparral, i-comfrey, i-dehydroepiandrosterone (i-DHEA), i-germander, i-kava, ioyile ye-pennyroyal, igwele elibomvu, kunye nezinye.

Iherbs kunye nezongezo ezinokucothisa igazi

I-Niacinamide inokucothisa ukujiya kwegazi. Sebenzisa i-niacinamide kunye namanye amayeza kunye nokuncedisa okucothisa ukujiya kwegazi kunokunyusa umngcipheko wokopha kwabanye abantu. Amanye amayeza alolu hlobo abandakanya i-angelica, i-clove, i-danshen, igalikhi, ijinja, iPanax ginseng, kunye nabanye.

Akukho kunxibelelana kwaziwayo nokutya.

La machiza alandelayo afundwe kuphando lwezesayensi:

ABADALA

NGOMLOMO:

• Ngokubanzi: Ezinye iimveliso ezongezwayo zokutya zisenokungadwelisi i-niacinamide ngokwahlukileyo kwileyibhile. Endaweni yoko, inokudweliswa phantsi kwe-niacin. I-Niacin ilinganiswa ngokulingana ne-niacin (NE). Idosi ye-1 mg ye-niacinamide iyafana ne-1 mg NE. Izibonelelo zokutya ezicetyiswayo mihla le (ii-RDAs) ze-niacinamide kubantu abadala zi-16 mg NE zamadoda, i-14 mg NE yabasetyhini, i-18 mg NE yabasetyhini abakhulelweyo, kunye ne-17 mg NE yabasetyhini abancancisayo.
• NgamaqhakuvaIitafile eziqukethe i-750 mg ye-niacinamide, i-25 mg ye-zinc, i-1.5 mg yobhedu, kunye ne-500 mcg ye-folic acid (iNicomide) kube kanye okanye kabini imihla ngemihla. Kwakhona, iipilisi ze-1-4 eziqukethe i-niacinamide, i-azelaic acid, i-zinc, i-vitamin B6, ithusi kunye ne-folic acid (i-NicAzel, i-Elorac Inc., iVernon Hills, IL) zithathwa yonke imihla.
• Kwiimpawu zokunqongophala kukavithamini B3 ezifana nepellagra: 300-500 mg ngemini ye-niacinamide inikwa ngeedosi ezahluliweyo.
• Isifo seswekile: Niacinamide 1.2 grams / m² (umphezulu womzimba) okanye i-25-50 mg / kg isetyenziselwa yonke imihla ukucothisa ukuqhubela phambili kohlobo lweswekile 1. Kwakhona, i-0.5 yeigram ye-niacinamide kathathu yonke imihla isetyenziselwa ukucothisa ukuqhubela phambili kohlobo lweswekile yesi-2.
• Kumanqanaba aphezulu e-phosphate egazini (hyperphosphatemia): I-Niacinamide ukusuka kwi-500 mg ukuya kwi-1.75 gram yonke imihla kwiidosi ezahluliweyo isetyenziselwa iiveki eziyi-8-12.
• Ngomhlaza wengqulaI-60 mg / kg ye-niacinamide inikwa iiyure eziyi-1-1.5 ngaphambi kokuphefumla i-carbogen (2% ye-carbon dioxide kunye ne-98% yeoksijini) ngaphambi nangexesha le-radiotherapy.
• Ngomhlaza wesikhumba ngaphandle kwe-melanoma: 500 mg ye-niacinamide kanye okanye kabini imihla ngemihla kwiinyanga ezi-4-12.
• Unyango lwe-osteoarthritis: Iigrama ezi-3 ze-niacinamide ngosuku ngeedosi ezahlulwe kangangeeveki ezili-12.

ESILWENI:

• Amabala: Ijeli ene-4% niacinamide kabini yonke imihla.

ABANTWANA

• NgokubanziIzibonelelo zokutya ezicetyiswayo zemihla ngemihla (ii-RDAs) ze-niacinamide ebantwaneni zi-2 mg yeentsana ezinenyanga ezi-0-6, i-4 mg NE yabantwana kwiinyanga eziyi-7-12 ubudala, i-6 mg NE yabantwana abaneminyaka eyi-1-3, 8 I-mg NE yabantwana abaneminyaka eyi-4-8 ubudala, i-12 mg NE yabantwana abaneminyaka engama-9-13 ubudala, i-16 mg NE ngamadoda aneminyaka eyi-14-18 ubudala, kunye ne-14 mg NE yabasetyhini abaneminyaka eli-14-18 ubudala.
• Ngamaqhakuva: Kubantwana abaneminyaka eli-12 ubuncinci ubudala, iipilisi ezi-1-4 eziqukethe i-niacinamide, i-azelaic acid, i-zinc, i-vitamin B6, ubhedu, kunye ne-folic acid (NicAzel, Elorac Inc., Vernon Hills, IL) zithathwa yonke imihla.
• Iipellagra: 100-300 mg ye-niacinamide inikwa yonke imihla ngeedosi ezahluliweyo.
• Uhlobo lwe-1 yeswekile: 1.2 iigram / m² (umphezulu womzimba) okanye i-25-50 mg / kg ye-niacinamide isetyenziselwa yonke imihla ukunciphisa inkqubela phambili okanye ukuthintela uhlobo lweswekile 1.

3-Pyridine Carboxamide, 3-Pyridinecarboxamide, Amide de l'Acide Nicotinique, B Complex Vitamin, Complexe de Vitamines B, Niacinamida, Nicamid, Nicosedine, Nicotinamide, Nicotinic Acid Amide, Nicotylamidum, Pyridine-3-carboxamide, , IVithamini B3.

Ukuze ufunde okungakumbi malunga nokubhalwa kweli nqaku, nceda ubone Amayeza endalo aVimba weDatha indlela yokusebenza.

1. UZhang Y, Ma T, Zhang P. Ukusebenza kunye nokukhuseleka kwe-nicotinamide kwi-phosphorus metabolism kwizigulana ze-hemodialysis: Uhlalutyo lwenkqubo kunye nohlalutyo lwe-meta. Amayeza (iBaltimore). 2018; 97: e12731. Jonga i-abstract.
2. I-Cannizzaro MV, i-Dattola A, i-Garofalo V, i-Del Duca E, i-Bianchi L. Ukunciphisa i-isotretinoin yomlomo yeziphumo ebezingalunganga: ukusebenza kwe-8% ye-omega-ceramides, iswekile ye-hydrophilic, i-5% ye-niacinamide cream compound kwizigulana zamabala. G Ital iDermatol Venereol. Ngo-2018; 153: 161-164. Jonga i-abstract.
3. Iziko lokuziqhelanisa neKlinikhi e-NICE (e-UK). I-Hyperphosphataemia kwiZifo zeZintso eziNgapheliyo: Ulawulo lweHyperphosphataemia kwizigulana ezinesigaba 4 okanye 5 sezifo zezintso ezingapheliyo. IZiko leSizwe lezeMpilo kunye noKhathalelo oluGqwesileyo: Izikhokelo zeKlinikhi. IManchester: iZiko leSizwe lezeMpilo kunye noKhathalelo oluGqwesileyo (e-UK); 2013 uMatshi.
4. U-Cheng SC, u-DO omncinci, u-Huang Y, u-Delmez JA, u-Coyne DW. Isilingo esilawulwa ngokungacwangciswanga, esingaboniyo, esilawulwa yi-placebo se-niacinamide sokunciphisa i-phosphorus kwizigulana ze-hemodialysis. Iiklinikhi J Am Soc Nephrol. U-2008 uJulayi; 3: 1131-8. Jonga i-abstract.
5. IHoskin PJ, iRojas AM, iBentzen SM, iSaunders MI. I-Radiotherapy ene-carbogen efanayo kunye ne-nicotinamide kwi-bladder carcinoma. J Ikliniki ye-Oncol. Ngo-2010 uNov 20; 28: 4912-8. Jonga i-abstract.
6. USurjana D, iHolo Holiday GM, uMartin AJ, uMoloney FJ, uDamian DL. I-nicotinamide yomlomo inciphisa i-keratoses ye-actinic kwisigaba II iimvavanyo ezilawulwa kabini ezingaboniyo. J Tyala iDermatol. Ngo-2012 ngoMeyi; 132: 1497-500. Jonga i-abstract.
7. I-Omidian M, i-Khazanee A, i-Yaghoobi R, i-Ghorbani AR, i-Pazyar N, i-Beladimousavi SS, i-Ghadimi M, i-Mohebbipour A, i-Feily A. Unyango lwe-nicotinamide yomlomo kwi-uremic pruritus engafunekiyo. I-Saudi J Kidney Dis Transpl. Ngo-2013 Sep; 24: 995-9. Jonga i-abstract.
8. INijkamp MM, Span PN, Terhaard CH, Doornaert PA, Langendijk JA, van den Ende PL, de Jong M, van der Kogel AJ, Bussink J, uKaanders JH. Ukukhula kwe-Epidermal factor receptor expression kwi-laryngeal cancer kuqikelela isiphumo sokuguqulwa kwehypoxia njengesongezo esikhawulezayo sonyango lwe-radiotherapy kwilingo elilawulwa ngokungahleliwe. Umhlaza we-Eur J. Ngo-2013 ngo-Okthobha; 49: 3202-9. Jonga i-abstract.
9. UMartin AJ, Chen A, uChoy B, et al. I-nicotinamide yomlomo yokunciphisa umhlaza we-actinic: Isigaba sesi-3 sesilingo esilawulwa kabini esingaboniyo. J Clin Oncol 33, 2015 (suppl; abstr 9000).
10. U-Lee DH, Oh IY, Koo KT, Suk JM, Jung SW, Park JO, Kim BJ, Choi YM. Ukuncitshiswa kobushushu emzimbeni emva konyango ngokudityaniswa kwe-niacinamide ye-topical kunye ne-tranexamic acid: ityala elilawulwa ngokungahleliwe, eliyimfama kabini, elilawulwa yimoto. Ulusu Res Technol. Ngo-2014 ngoMeyi; 20: 208-12. Jonga i-abstract.
11. Khodaeiani E, Fouladi RF, Amirnia M, Saeidi M, Karimi ER. Imixholo ye-4% ye-nicotinamide vs 1% ye-clindamycin kwi-acne vulgaris ephakathi. Int J Dermatol. Ngo-2013 Agasti; 52: 999-1004. Jonga i-abstract.
12. UJanssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, Chin A, Takes RP, de Bree R, Hoogsteen IJ, Bussink J, Span PN, Kaanders JH. Ukuphuculwa kokuphindaphinda okungenasiphelo kunye neARCON kwizigulana ezinomhlaza womhlaza. Umhlaza weklinikhi Res. Ngo-2014 ngoMatshi 1; 20: 1345-54. Jonga i-abstract.
13. UJanssens GO, Rademakers SE, Terhaard CH, Doornaert PA, Bijl HP, van den Ende P, Chin A, Marres HA, de Bree R, van der Kogel AJ, Hoogsteen IJ, Bussink J, Span PN, Kaanders JH. Ukukhawulezisa i-radiotherapy nge-carbogen kunye ne-nicotinamide yomhlaza we-laryngeal: iziphumo zesigaba sesithathu sesilingo esingahleliwe. J Ikliniki ye-Oncol. Ngo-2012 ngoMeyi 20; 30: 1777-83. Jonga i-abstract.
14. UFabbrocini G, uCantelli M, uMonfrecola G. Imixholo ye-nicotinamide ye-seborrheic dermatitis: isifundo esivulekileyo esivulekileyo. Unyango lweJ Dermatolog. Ngo-2014 uJuni; 25: 241-5. Jonga i-abstract.
15. I-Eustace A, Irlam JJ, Taylor J, Denley H, Agrawal S, Choudhury A, Ryder D, Ord JJ, Harris AL, Rojas AM, Hoskin PJ, West CM. I-Necrosis iqikelela ukuxhamla kwi-hypoxia-modifying therapy kwizigulana ezinomngcipheko omkhulu womhlaza wesinyi obhalise kwisigaba sesi-III solingo olungenamkhethe. Radiother Oncol. Ngo-2013 ngoJulayi; 108: 40-7. Jonga i-abstract.
16. Amengual JE, Clark-Garvey S, Kalac M, Scotto L, Marchi E, Neylon E, Johannet P, Wei Y, Zain J, O'Connor OA. I-Sirtuin kunye ne-pan-class I / II deacetylase (DAC) inhibition yolungelelwaniso kwiimodeli zangaphambi kwexesha kunye nezifundo zeklinikhi ye-lymphoma. Igazi. Ngo-2013 Sep 19; 122: 2104-13. Jonga i-abstract.
17. Shalita AR, Falcon R, Olansky A, Iannotta P, Akhavan A, Usuku D, Janiga A, Singri P, Kallal JE. Ulawulo lwe-acne lokudumba kunye nenoveli yokutya yokutya. J Iziyobisi iDermatol. Ngo-2012; 11: 1428-33. Jonga i-abstract.
18. UFalsini, B., Piccardi, M., Iarossi, G., Fadda, A., Merendino, E., kunye noValentini, P. Impembelelo yokongezwa kwexesha elifutshane le-antioxidant ekusebenzeni kwe-macular kwi-maculopathy enxulumene nobudala: isifundo somqhubi kubandakanya Uvavanyo lwe-electrophysiologic. Ophthalmology 2003; 110: 51-60. Jonga i-abstract.
19. U-Elliott RB, uPilcher CC, uStewart A, uFergusson D, uMcGregor MA. Ukusetyenziswa kwe-nicotinamide kuthintelo lohlobo 1 lweswekile. UAnn N Y Acad Sci. Ngo-1993; 696: 333-41. Jonga i-abstract.
20. URottembourg JB, uLaunay-Vacher V, uMassard J. Thrombocytopenia obangelwa yi-nicotinamide kwizigulana ze-hemodialysis. Izintso Int. Ngo-2005; 68: 2911-2. Jonga i-abstract.
21. UTakahashi Y, Tanaka A, uNakamura T, et al. INicotinamide icinezela i-hyperphosphatemia kwizigulana ze-hemodialysis. Izintso Int. Ngo-2004; 65: 1099-104. Jonga i-abstract.
22. USoma Y, Kashima M, Imaizumi A, et al. Iziphumo zokuthambisa i-nicotinamide yesihloko kulusu olomileyo lwe-atopic. Int J Dermatol. Ngo-2005; 44: 197-202. Jonga i-abstract.
23. UPowell ME, Hill SA, Saunders MI, Hoskin PJ, uChaplin DJ. Ukuhamba kwegazi kwithumba lomntu kuyonyuswa yi-nicotinamide kunye nokuphefumla kwe-carbogen. Umhlaza Res. Ngo-1997; 57: 5261-4. Jonga i-abstract.
24. IHoskin PJ, iRojas AM, iPhillips H, iSaunders MI. Ukugula okunamandla kunye nokufika kade kunyango lwe-bladder carcinoma ene-radiotherapy ekhawulezileyo, i-carbogen kunye ne-nicotinamide. Umhlaza. 2005; 103: 2287-97. Jonga i-abstract.
25. INiren NM, iTorok HM. Ukuphuculwa kweNicomide kuPhando lweZiphumo zeKlinikhi (i-NICOS): iziphumo zolingo lweeveki ezisi-8. I-Cutis. Ngo-2006; 77 (1 iSuppl): 17-28. Jonga i-abstract.
26. I-Kamal M, Abbasy AJ, Muslemani AA, Bener A. Iziphumo ze-nicotinamide kuhlobo olutsha olusandul 'ukufumanisa isifo seswekile. Acta Pharmacol Isono. Ngo-2006; 27: 724-7. Jonga i-abstract.
27. I-Olmos PR, iHodgson MI, iMaiz A, et al. INicotinamide ikhusele inqanaba lokuqala lokuphendula kwe-insulin (FPIR) kunye nokuthintela isifo seklinikhi kwizalamane zokuqala zohlobo lwesifo seswekile. Ukuziqhelanisa neklinikhi yeswekile. Ngo-2006; 71: 320-33. Jonga i-abstract.
28. IGale EA, iBingley PJ, i-Emmett CL, iCollier T; Iqela laseYurophu laseNicotinamide leSifo seSwekile sokuNgenelela (ENDIT) Iqela. I-European Nicotinamide Diabetes Intervention Trial (ENDIT): ityala elilawulwa ngononophelo longenelelo ngaphambi kokuqala kohlobo lweswekile 1. ILancet. Ngo-2004; 363: 925-31. Jonga i-abstract.
29. UCabrera-Rode E, uMolina G, u-Arranz C, uVera M, et al. Iziphumo ze-nicotinamide esemgangathweni kuthintelo lwesifo seswekile sokuqala kwinqanaba lezihlobo zabantu abanesifo seswekile sokuqala. Ukuzenzekelayo. Ngo-2006; 39: 333-40. Jonga i-abstract.
30. UHakozaki T, uMinwalla L, uZhuang J, et al. Iziphumo ze-niacinamide ekunciphiseni i-pigmentation cutaneous and suppression of melanosome transfer. UBr J Dermatol. Ngo-2002 ngoJulayi; 147: 20-31. Jonga i-abstract.
31. I-Bissett DL, i-Oblong JE, iBerge CA. I-Niacinamide: I-vitamin B ephucula ukubonakala kwesikhumba ebusweni. Utyando lweDermatol. 2005; 31 (7 iPt 2): 860-5; ingxoxo 865. Jonga into engaqondakaliyo.
32. UJorgensen J. Pellagra mhlawumbi ngenxa yepyrazinamide: ukukhula ngexesha lokudityaniswa kwemichiza yesifo sephepha. Int J Dermatol 1983; 22: 44-5. Jonga i-abstract.
33. Swash M, uRoberts AH. Ukubuyiselwa kwakhona kwe-pellagra-encephalopathy kunye ne-ethionamide kunye ne-cycloserine. Ityhubhu 1972; 53: 132. Jonga i-abstract.
34. I-Brooks-Hill RW, uBhishophu ME, uVellend H. Ndingu-Rev Ukuphendula ngo-1985; 131: 476. Jonga i-abstract.
35. IVisalli N, uCavallo MG, uMqondiso u-A, et al. Uvavanyo oluneziko elinamacala amaninzi elinamanani amabini ahlukeneyo e-nicotinamide kwizigulana ezinohlobo lwangoku lwesifo seswekile (IMDIAB VI). Isifo seswekile iMetab Res Rev 1999; 15: 181-5. Jonga i-abstract.
36. IBourgeois BF, uDodson WE, uFerrendelli JA. Ukudibana phakathi kwe-primidone, carbamazepine, kunye ne-nicotinamide. Neurology 1982; 32: 1122-6. Jonga i-abstract.
37. Utata CM. I-Niacinamide kunye ne-acanthosis nigricans (ileta). IArch Dermatol 1984; 120: 1281. Jonga i-abstract.
38. Ubusika SL, uBoyer JL. Ityhefu ye-hepatic evela kwiidosi ezinkulu zevithamini B3 (nicotinamide). N Engl J Med 1973; 289: 1180-2. Jonga i-abstract.
39. UMcKenney J. Iimbono ezintsha ngokusetyenziswa kwe-niacin kunyango lweengxaki ze-lipid. IArch Intern Med 2004; 164: 697-705. Jonga i-abstract.
40. Ukuphakamisa i-HDL kunye neNiacin Sebenzisa. Ileta ka-Pharmacist / I-Prescriber's Letter 2004; 20: 200504.
41. IHoskin PJ, iStratford MR, iSaunders MI, okqhubekayo. Ulawulo lwe-nicotinamide ngexesha letshathi: i-pharmacokinetics, ukunyuka kwedosi, kunye netyhefu yeklinikhi. I-Int J Radiat Oncol Biol Phys 1995; 32: 1111-9. Jonga i-abstract.
42. UFatigante L, uDucci F, uCartei F, et al. I-Carbogen kunye ne-nicotinamide edityaniswe ne-radiotherapy engaqhelekanga kwi-glioblastoma multiforme: unyango lwendlela entsha. I-Int J Radiat Oncol Biol Phys 1997; 37: 499-504. Jonga i-abstract.
43. UMiralbell R, uMornex F, uGreiner R, et al. Ukukhawulezisa i-radiotherapy, i-carbogen, kunye ne-nicotinamide kwi-glioblastoma multiforme: ingxelo yoMbutho waseYurophu woPhando kunye noNyango lovavanyo lweCancer 22933. J Clin Oncol 1999; 17: 3143-9. Jonga i-abstract.
44. Anon. I-Niacinamide Monograph. U-Alt Med ngo-2002; 7: 525-9. Jonga i-abstract.
45. IHaslam RH, iDalby JT, iRademaker AW. Iziphumo zonyango lwe-megavitamin ebantwaneni abanengxaki yokusilela ekuqwalaseleni. Pediatrics 1984; 74: 103-11 .. Jonga i-abstract.
46. Ukutya kunye neBhodi yeZondlo, iZiko lezeMpilo. Ukufakwa kwereferensi yokutya kwi-Thiamin, i-Riboflavin, i-Niacin, i-Vitamin B6, i-Folate, i-Vitamin B12, i-Pantothenic Acid, i-Biotin kunye ne-Choline. IWashington, DC: ICandelo leSizwe lezeMfundo, 2000. Iyafumaneka kwi: http://books.nap.edu/books/0309065542/html/.
47. UShalita AR, uSmith JG, uParish LC, et al. Imixholo nicotinamide xa kuthelekiswa nejeli yeclindamycin kunyango lwe-acne vulgaris. I-Int J Dermatol 1995; 34: 434-7. Jonga i-abstract.
48. UMcCarty MF, uRussell AL. Unyango lwe-Niacinamide lwe-osteoarthritis-ngaba luyayithintela i-nitric oxide synthase induction yi-interleukin 1 kwii-chondrocytes? Iingcinga ze1999; 53: 350-60. Jonga i-abstract.
49. UJonas WB, uRapoza CP, uBlair WF. Iziphumo ze-niacinamide kwi-osteoarthritis: isifundo somqhubi. Ukuvuvukala kwe1996; 45: 330-4. Jonga i-abstract.
50. IPolo V, Saibene A, iPontiroli AE. I-Nicotinamide iphucula ukugcinwa kwe-insulin kunye nolawulo lwe-metabolic kuhlobo olucekeceke lwe-2 yezigulana ezinesifo seswekile ezingaphumeleliyo kwisulphonylureas. Umthetho weswekile ka-1998; 35: 61-4. Jonga i-abstract.
51. IGreenbaum CJ, iKahn SE, iPalmer JP. Iziphumo zikaNicotinamide kwi-glucose metabolism kwizifundo ezisemngciphekweni we-IDDM. Iswekile 1996; 45: 1631-4. Jonga i-abstract.
52. I-Pozzilli P, i-Browne PD, i-Kolb H. Meta-uhlalutyo lonyango lwe-nicotinamide kwizigulana ezine-IDDM yakutshanje. Abavavanyi beNicotinamide. Unonophelo lweSwekile 1996; 19: 1357-63. Jonga i-abstract.
53. I-Pozzilli P, iVisalli N, iSayinaore A, et al. Uvavanyo oluphindwe kabini lwe-nicotinamide kwi-IDDM yakutshanje (isifundo se-IMDIAB III). Iswekile 1995; 38: 848-52. Jonga i-abstract.
54. IVisalli N, uCavallo MG, uMqondiso u-A, et al. Uvavanyo oluneziko elinamacala amaninzi elinamanani amabini ahlukeneyo e-nicotinamide kwizigulana ezinohlobo lwangoku lwesifo seswekile (IMDIAB VI). Isifo seswekile iMetab Res Rev 1999; 15: 181-5. Jonga i-abstract.
55. UPozzzilli P, uVisalli N, uCavallo MG, et al. I-Vitamin E kunye ne-nicotinamide zineempembelelo ezifanayo ekugcineni intsalela yokusebenza kweseli ye-beta kwisifo seswekile esixhomekeke kutshanje. I-Eur J Endocrinol 1997; 137: 234-9. Jonga i-abstract.
56. ILampeter EF, iKlinghammer A, iSherbaum WA, et al. Isifundo songenelelo ngoncedo seDeutsche Nicotinamide: ukuzama ukuthintela uhlobo lweswekile 1. Iqela le-DENIS. Iswekile 1998; 47: 980-4. Jonga i-abstract.
57. U-Elliott RB, uPilcher CC, uFergusson DM, uStewart AW. Isicwangciso esisekwe kubemi sokuthintela isifo seswekile esixhomekeke kwi-insulin usebenzisa i-nicotinamide. J wePediatr Endocrinol Metab 1996; 9: 501-9. Jonga i-abstract.
58. Gale EA. Ithiyori kunye nokuziqhelanisa novavanyo lwe-nicotinamide kuhlobo lwangaphambi kohlobo lwe-1 lweswekile. J wePediatr Endocrinol Metab 1996; 9: 375-9. Jonga i-abstract.
59. I-Kolb H, iBurkart V. Nicotinamide kuhlobo 1 lweswekile. Inkqubo yentshukumo iphinde yaqwalaselwa. Unonophelo lweSwekile 1999; 22: B16-20. Jonga i-abstract.
60. Umbutho waseMelika wezeMpilo kwiNkqubo yezeMpilo. INgxelo yoBume boNyango lwe-ASHP ngokusetyenziswa okukhuselekileyo kwe-niacin kulawulo lwe-dyslipidemias. NdinguJ J Health Syst Pharm 1997; 54: 2815-9. Jonga i-abstract.
61. UGarg A, uGrundy SM. I-Nicotinic acid njengonyango lwe-dyslipidemia kwisifo seswekile esingaxhomekekanga kwi-insulin. IJAMA 1990; 264: 723-6. Jonga i-abstract.
62. Ikhonkco JR III. Uphuhliso olutsha ekusetyenzisweni kwe-niacin kunyango lwe-hyperlipidemia: ukujonga okutsha ekusebenziseni ichiza elidala. ICoron Artery Dis 1996; 7: 321-6. Jonga i-abstract.
63. I-Brenner A. Iziphumo ze-megadoses ye-B ekhethiweyo yeevithamini ezinzima kubantwana abane-hyperkinesis: izifundo ezilawulwayo kunye nokulandelwa kwexesha elide. J Funda ukukhubazeka 1982; 15: 258-64. Jonga i-abstract.
64. IiYates AA, iSchlicker SA, iSuitor CW. Ukungeniswa kwereferensi yezidlo J Nditya i-Assoc 1998; 98: 699-706. Jonga i-abstract.
65. Shils ME, Olson JA, Shike M, Ross AC, ii-eds. Isondlo sangoku kwezempilo nakwizifo. Umhla we-9. IBaltimore, MD: UWilliams kunye noWilkins, ngo-1999.
66. IHarvengt C, iDesager JP. Ukunyuka kwe-cholesterol ye-HDL kwizifundo ze-normolipaemic kwi-khellin: isifundo somqhubi. I-Int J Clin Pharmacol Res 1983; 3: 363-6. Jonga i-abstract.
67. UHardman JG, uLimbird LL, uMolinoff PB, ii-eds. UGoodman noGillman's Isiseko seFarmacological of Therapeutics, umhla we-9. ENew York, NY: McGraw-Hill, 1996.
68. UMcEvoy GK, ed. Ulwazi lwe-AHFS yeziyobisi. I-Bethesda, MD: Umbutho waseMelika we-Health-System Pharmacists, 1998.
69. Blumenthal M, ed. IKhomishini epheleleyo yaseJamani i-E Monographs: Isikhokelo sonyango kumaYeza eHerbal. Dlulisa. S. Klein. IBoston, MA: IBhunga laseMelika leBhotani, i-1998.

Ukuhlaziywa kokugqibela-10/05/2020